INTRODUCTION
The closed circulatory system consists of a network of blood vessels in vertebrates, and is essential for the development and maintenance of all tissues in the body. Through the blood vessels, tissues receive oxygen and nutrition, and remove CO2 and final metabolites such as urea and lactic acid. In addition to blood vessels, the body has another tubular network, the lymph vessel system. Blood vessels leak liquid with nutrients into tissues, but this fluid is efficiently absorbed by lymph vessels and returned into the circulatory system without tissue edema.
Under pathological conditions, tumors stimulate angiogenesis, the formation of blood vessels, and take oxygen and nutrition for rapid growth (1) . Furthermore, tumors utilize blood vessels and lymph vessels for metastasis to other tissues and lymph nodes. Severe inflammatory diseases also induce pathological angiogenesis as a malignant step. The main regulator for angiogenesis is now known to be the VEGF and VEGFR system (2, 3) , and various inhibitors of this system are widely used for the treatment of solid tumors. These inhibitors significantly improve the quality of life and survival of patients, but as yet are not a cure. Here, I mainly describe VEGF-VEGFRs and their inhibitors. Finally, I discuss the resistance of tumors to drugs, and problems to be overcome.
VEGF family
The VEGF family belongs to the platelet-derived growth factor (PDGF)/VEGF supergene family, having a homodimer structure with 8 conserved cysteine residues in a monomer peptide ( Fig.  1, 2) (2, 4) . The VEGF family has at least 7 members, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, PlGF and snake venom-derived VEGFs such as T.f. (Trimeresurus flavoviridis) svVEGF (3, 5) . All members except VEGF-E and svVEGF are encoded in the mammalian genome. VEGF-A is a key player in vasculogenesis, the formation of blood vessels from progenitor cells, as well as angiogenesis. Surprisingly, not only homozygotes but heterozygotes for the VEGF-A gene (VEGF-A+/-mice) die in the embryonic stage due to a variety of defects in angiogenesis, indicating that the basal level of VEGF-A protein supplied from two alleles is essential for completion of the formation of a closed circulatory system (6, 7).
Subtype of VEGF-A
VEGF-A binds and activates VEGFR1 and VEGFR2 but not VEGFR3. The major subtypes of VEGF-A in humans are the 121, 165, and 189-amino acid types (2) . VEGF-A121 does not contain a basic stretch, whereas VEGF-A165 and VEGF-A189 carry basic stretches in the carboxyl terminal region. VEGF-A165 is the dominant subtype among VEGF-A proteins in terms of amount and biological activity. Via its basic stretch, VEGF-A165 modestly binds http://bmbreports.org BMB reports In tumor tissues, the VEGF-VEGFR system stimulates pathological angiogenesis in a complicated network with other signaling pathways. , and VEGF-A 188/188 mice) are embryonic lethal, indicating that VEGF-A164 is essential and sufficient for normal development of blood vessels in mice (9).
Regulation of VEGF-A gene expression
The expression of the VEGF-A gene is upregulated via hypoxia (10, 11) , estrogen, NF-κB pathways, and others. Under hypoxic conditions, HIFα proteins (HIF1α and HIF2α) are stabilized due to a block of ubiquitin-dependent degradation. Since VHL (von Hippel-Lindau) protein plays a major role in the degradation of HIFα, renal cell carcinoma patients carrying a VHL-gene-deficiency (von Hippel-Lindau syndrome) generally show high levels of VEGF-A mRNA and protein in tumor tissues, and strong tumor angiogenesis.
PlGF and VEGF-B
These ligands bind and activate only VEGFR1. Since the tyrosine kinase activity of VEGFR1 is one order of magnitude weaker than that of VEGFR2, the angiogenic activity of PlGF and VEGF-B is usually about 10-fold weaker than that of VEGF-A. Under pathological conditions, however, an increased amount of PlGF as well as VEGF-A recruits bone-marrow-derived monocytes/macrophages via VEGFR1 to cancer tissues or inflammatory lesions, and significantly enhances pathological angiogenesis (12) (13) (14) (15) .
VEGF-C and -D: crucial regulators of lymphangiogenesis
VEGF-C and VEGF-D are originally synthesized in premature forms, and processed by digestion with furin and other proprotein convertases to shortest forms (16) . After processing, they acquire a strong ability to bind VEGFR3, and induce lymphangiogenesis.
The VEGF-C gene starts to be expressed early in embryogenesis, and plays an essential role in the development of lymphatic endothelial cells from veins at E9.5-10.5 in mice. Not only homozygotes but also heterozygotes for the VEGF-C allele (VEGF-C +/-mice) often die in the perinatal stage due to a dysfunction of lymph vessels, severe systemic edema and the accumulation of lipids in body fluids. This indicates that half the normal level of VEGF-C protein is insufficient for the absorption of tissue fluids and lipids. VEGF-C or VEGF-D-overexpressing tumors are lymphangiogenic and highly metastatic to lymph nodes, thus, these ligands are important targets for suppression of lymph-node metastasis.
VEGF-E and T.f. svVEGF: a unique utilization of VEGFRs VEGF-E (also known as Orf VEGF) proteins are encoded in the genome of Orf virus (sheep/goat parapox-virus), and consist of about 120-140-amino acid long peptides (17) . Eight cysteine residues in the monomer peptide are highly conserved similar to other VEGF/PDGF family members, and activate VEGFR. However, unlike VEGF-A, VEGF-E family proteins such as VEGF-ENZ2, VEGF-ENZ7 and VEGF-ED1701 bind and activate only VEGFR2, not VEGFR1 (18) (19) (20) . We found that, unlike VEGF-A, VEGF-E induces angiogenesis with very low of the "side effects", such as edema, cytokine production and inflammatory reactions, commonly observed both on VEGF-A treatment and in VEGF-A transgenic mice (Fig. 2) (21-24) . These unique characteristics of VEGF-E indicate humanized VEGF-Es to be good candidates for proangiogenic agents (25) (26) (27) .
T.f. (Trimeresurus flavoviridis) svVEGF is a VEGF-like protein purified from snake venom called "Habu-toxin", which was obtained from Habu-snakes living in Southern Japan. Interestingly, T.f. svVEGF binds tightly with VEGFR1 but weakly with VEGFR2, resulting in strong vascular permeability activity with only weak angiogenic activity (28) . This perme-http://bmbreports.org ability-dominant activity of T.f. svVEGF may be a result of its unique VEGFR1-dominant/VEGFR2-weak activation in vascular endothelial cells, and is considered important for the snakes to rapidly distribute the real toxins in their venom into target animals.
VEGF receptors
The VEGFR family consists of three members, VEGFR1, VEGFR2 and VEGFR3, and is structurally distantly related to the PDGFR family (Fig. 2) . PDGFR family receptor tyrosine kinases have 5 immunoglobulin-like (Ig) domains in the extracellular region, whereas VEGFRs have 7 Ig domains (29) (30) (31) (32) . VEGFR1 and VEGFR2 bind VEGF-A, and play a central role in the regulation of angiogenesis, whereas VEGFR3 tightly binds VEGF-C and -D, and stimulates lymphangiogenesis (33, 34) .
VEGFR1/Flt-1 (Fms-like tyrosine kinase-1): flt-1 TK-/-mice are useful for analysis of VEGFR1 signaling in various diseases
VEGFR1 has a very high affinity for VEGF-A at Kd= 2 to 10 pM, however, its tyrosine kinase activity is weak, about 10-fold lower than that of VEGFR2. Based on this weak activity, under physiological conditions, VEGFR1 only weakly stimulates endothelial proliferation. VEGFR1 is expressed not only on vascular endothelial cells but also in monocyte/macrophage-lineage cells, and stimulates migration of these bone-marrow-derived cells (35) (36) (37) . Macrophages that have migrated via VEGF-A (or PlGF)-VEGFR1 signaling into tumor tissues or inflammatory areas stimulate pathological angiogenesis as well as lymphangiogenesis by secretion of VEGF-A, VEGF-C, and other cytokines (15, (38) (39) (40) .
VEGFR1-null mutant mice die at E8.5-9.0 due to an overgrowth and dysfunction of blood vessels, suggesting a negative role of VEGFR1 in angiogenesis early in embryogenesis (41) . Surprisingly, VEGFR1 tyrosine kinase domain-deficient mice (flt-1 TK-/-mice) are basically healthy, thus, the negative role of VEGFR1 is dependent on the extracellular region, most likely by trapping the endogenous VEGF-A to decrease its local concentration (42) .
flt-1 TK-/-mice under physiological conditions have no phenotype except for a minor reduction of osteoclasts in bone marrow, but under pathological conditions such as rheumatoid arthritis (RA) and cancer, the levels of malignancy of these diseases are significantly reduced. In the RA model, inflammatory cell infiltration was strongly decreased, and inflammation at the joints was much less extensive in flt-1 TK-/-mice than in wild-type mice. In a tumor transplantation model, tumor growth at local sites decreased accompanied by less infiltration of macrophages and less angiogenesis. Premetastatic induction of MMP9 in distant tissues was about one-third, and the degree of metastasis was significantly reduced in flt-1 TK-/-mice compared with wild-type mice (13) . Treatment of tumor-bearing wild-type mice with anti-VEGFR1 neutralizing antibody resulted in a similar reduction in metastasis (43) .
Soluble VEGFR1 (sFlt-1): an important mediator in preeclampsia
The VEGFR1 gene expresses two types of mRNA, one for the full-length VEGFR1 receptor, and another for the ligand-binding region alone as a secreted soluble protein (sFlt-1) (30, 44) . This unique feature is conserved not only in mammals but also in other animals including birds and amphibians, suggesting a crucial role in embryogenesis (45) . The level of sFlt-1 protein was reported to be abnormally high in the serum of preeclampsia patients, and recent studies indicated that abnormal trapping of natural VEGF-A with a large amount of sFlt-1 results in hypertension and proteinuria, the major symptoms on the maternal side of preeclampsia (46) (47) (48) . Thus, sFlt-1 is an important target in the treatment of preeclampsia.
VEGFR1 is reported to have other functions, and a recent report described that VEGFR1 is involved in the maintenance of cancer stem cells in certain type of tumors by stimulating survival signals in the cells (49) (50) .
VEGFR2: a single autophosphorylation at 1175-tyrosine plays a major role in signaling for angiogenesis VEGFR2 (KDR in humans, Flk-1 in mice) exhibits strong tyrosine kinase activity although its ability to bind with VEGF-A is about one order of magnitude weaker than that of VEGFR1. flk-1 (-/-) mice die at E8.5 due to a lack of blood vessels, indicating that VEGFR2-signaling is essential for the development of vascular systems in the embryo (51). We and others have shown that this receptor tyrosine kinase efficiently activates the PLCγ (phospholipase-Cγ) and PKC pathway, and its downstream c-Raf-MEK-MAP-kinase pathway towards DNA synthesis in endothelial cells (52, 53) . Activation of the Ras-pathway, which is involved in the signaling of representative tyrosine kinase receptors such as EGFR, is minor in VEGFR2 signaling. Furthermore, a single autophosphorylation site, 1175-tyrosine, is critical for the binding of PLCγ and activation of the PLCγ-PKC pathway (54) . The importance of 1175-tyrosine in vivo was proved by the finding that a phenylalanine mutation at this tyrosine in mice (flk-1 1173F/1173F mice) induces embryonic lethality at E8.5-9.0 due to a lack of development of blood vessels (Fig. 2) (53) .
VEGFR2 generates a variety of angiogenic signals not only for endothelial proliferation but for cell migration/morphogenesis including tubular formation. The 951-tyrosine was shown to regulate cell migration by binding with an adaptor, TSAd (56) . Nrp1, a co-receptor for VEGF-A165, binds the basic stretch of VEGF-A165, increases the affinity of VEGF-A165 for VEGFR2, and enhances signaling (57).
VEGFR3: an essential signal-transducer for lymphangiogenesis
VEGFR3 is mainly expressed in lymph-endothelial cells, and regulates lymphangiogenesis with its ligands, VEGF-C and -D (33, 58 ). An inactivation mutation at the VEGFR3 tyrosine kin-http://bmbreports.org BMB reports ase domain in humans results in familiar lymph-edema syndrome (Milroy disease) due to insufficient development of lymph vessel systems. The signaling pathway from VEGFR3 is not fully understood yet. PLCγ-PKC pathway was activated after VEGF-C stimulation (59) . On the other hand, activation of the Ras-pathway was also reported. It is of interest to see whether both pathways are equally activated or one of them plays a major role in lymphangiogenesis.
VEGF-VEGFR inhibitors applied for clinical use.

Anti-cancer drugs
Most of the solid tumors generated in breast, lung, renal, colorectal and liver tissues express high levels of VEGF-A compared to normal tissues due to hypoxic stress and the activation of oncogenes ( Fig. 3) (1). In addition, VEGF-A has strong vascular permeability activity, and significantly contributes to the formation of ascites tumors (4, 60). Anti-human VEGF-A neutralizing antibody was previously shown to significantly decrease the growth of transplantable human tumors in nude mice, suggesting the blocking of VEGF-A to be useful for the suppression of solid tumors in humans (61) . Bevacizumab (Avastin R : humanized anti-human VEGF-A neutralizing antibody) significantly improved the disease-free survival rate as well as overall survival rate in late-stage colorectal cancer patients in a phase-III clinical trial (Fig. 4) (62) , and has been approved by the Food and Drug Administration (FDA) in the U.S.A. for use in the treatment of stage-III-IV colorectal cancer in combination with chemotherapy. Bevacizumab was also approved for the treatment of non-squamous non-small cell lung cancers, the major type of which is pulmonary adeno-carcinoma (63) . The main reason that it has not been applied to squamous-type lung cancer is a risk of severe thrombosis and hemorrhage (64) .
Since VEGFR is a typical tyrosine kinase, various small chemicals that block kinase activity have been tested in the clinical field, and so far two such inhibitors, Sorafenib (Raf and VEGFR inhibitor) and Sunitinib (VEGFR and other tyrosine kinase inhibitors), have been approved for the treatment of renal cell carcinoma. These inhibitors significantly improved the survival of renal cell cancer patients compared with the previous therapeutic strategy using cytokines. Furthermore, in late 2007, the FDA approved Sorafenib for the treatment of hepatocellular carcinoma patients based on a clinical study (Fig. 5) .
VEGF and VEGFR inhibitors have significantly improved the survival and disease-free survival of patients with cancers. However, in several cancers such as pancreas cancer, these in-hibitors appear less effective or have almost no clear effect, probably due to less of a dependency of the growth and invasion of these tumors on pathological angiogenesis. Indeed, many pancreas cancer tissues were shown to be poorly angiogenic, and slowly invasive to surrounding tissues and lymph nodes than typical solid tumors such as colon cancer.
Anti age-related macular degeneration (AMD)
The level of VEGF-A is elevated in the retina of patients with malignant-type AMD, and induces pathological angiogenesis in the retina. An aptamer, an RNA-derivative-based molecule, which blocks activity of VEGF-A165 is approved by FDA, and widely used for the treatment of AMD. Furthermore, an anti-VEGF-A neutralizing antibody similar to bevacizumab was developed for the treatment of AMD, and found to be highly effective. Injection of the antibody into the eye significantly improved the visual activity of AMD patients.
Adverse effects of VEGF-VEGFR inhibitors
Three major side effects are seen in patients treated with these inhibitors; (1) hypertension, (2) proteinuria/renal dysfunction, and (3) thrombosis and hemorrhage. The molecular basis of this hypertension is still unclear, however, preeclampsia patients overexpressing sFlt-1 (soluble VEGFR1), a natural VEGF-A blocker, show hypertension, suggesting a similar mechanism in these two cases for the induction of high blood pressure. It might be due to too much blocking of physiological VEGF-A in the body, and this type of hypertension is usually controllable using regular anti-hypertensive drug(s).
Proteinuria caused by VEGF-signaling inhibitors is also common among inhibitor-treated cancer patients and preeclampsia patients, thus, it seems possible that strong inhibition of endogenous VEGF-A in the kidney impair the function of vascular endothelial cells in glomeruli of the kidney, resulting in the leakage of serum proteins from glomerular endothelial cells. To date, specific drugs for the treatment of this proteinuria have not been developed.
Thrombosis and hemorrhage are rare, but can be life threatening. These adverse effects may be tightly linked to the suppressive activity of VEGF-signal inhibitors toward the function and survival of endothelial cells in tumor angiogenesis. Thus, such side effects might not be easily avoided because the original effects of drugs were on the vascular systems. Specific drugs to suppress such side effects, abnormal bleeding and thrombosis, should be developed to increase the safety of VEGF-VEGFR inhibitors.
Resistance to VEGF-VEGFR inhibitors
At least two types of resistance to anti-VEGF or anti-VEGFR treatment could be considered to occur. The first is that the tumor cell itself (or tumor tissue itself) is originally less sensitive to anti-VEGF signaling drugs due to less of a dependency of tumors on the secreted VEGF-A, or on the VEGFR signaling. The former may be resistant to anti-VEGF-A antibody, and the latter may be resistant to VEGFR TK inhibitors. In the resistance to the anti-VEGF-A antibody, we should consider the possibility of an intracrine-autocrine loop of VEGF-VEGFR within the tumor endothelial cell apparatus such as Golgi apparatus (65) . In addition, other growth factors such as PlGF and VEGF-B may play a significant role in angiogenesis (66) . In the resistance to TK-inhibitors, intracellular signaling in endothelial cells via the Src-family, Ras-Raf, or PI3K-Akt pathway insensitive to the VEGFR TK inhibitors, might become major angiogenic signals in tumor tissues.
The second-type of resistance is an acquired resistance during the treatment of cancer patients with VEGF-VEGFR inhibitors. When anti-angiogenic therapy is very effective, much of the tumor vasculature seems to disappear due to apoptotic cell death and the "normalization" of blood vessels in tumor tissues. Due to this dramatic decrease in tumor angiogenesis, the supply of oxygen and nutrition to tumor cells may decrease in a short period of time, and tumor cells are placed under strong stress due to hypoxia and low nutrition. This stress induces massive tumor cell death, and the tumor's volume decreases significantly. However, as with other anti-cancer drugs, a few tumor cells might acquire resistance via intracellular metabolic change and/or via an increased invasive phenotype. The molecular basis underlying such phenotypes is still to be elucidated, thus, it is important to study further the VEGF-dependent pathway as well as VEGF-independent pathway for angiogenesis in mammals.
In the next few pages, I present a brief summary of the VEGF-independent regulation of angiogenesis since a number of review articles have already been published on this topic.
VEGF-independent regulation of angiogenesis Pro-angiogenic pathways
The Angiopoietin-Tie family and EphrinB2-EphB4 signaling systems are relatively specific to the vascular system (Fig. 1) . Ang1 stimulates mostly the PI3K-Akt pathway as a survival signal, and stabilizes blood vessels. Since natural Ang1 protein easily aggregates and is difficult to handle, an artificially modified Ang1 such as Comp-Ang1 or Ang1* may be useful for proangiogenic therapy (67, 68) . Ang2 acts as a partial agonist or antagonist of Ang1 signaling. When enough VEGF-A exists, the unstabilizing effect of Ang2 enhances angiogenic responses, however, with little or no VEGF, Ang2 is known to decrease angiogenesis via unstabilization of vessels and apoptosis of vascular endothelial cells.
EphrinB2-EphB4 is thought to regulate the differentiation of arteries and veins, being less effective for the proliferation of endothelial cells (69) . The Delta-Notch pathway is shown not only to regulate artery-vein differentiation but also to stimulate blood vessel formation (Fig. 1) PDGF is an important regulator of angiogenesis via stimulation of the proliferation and survival of smooth muscle cells and pericytes. However, at least in certain culture conditions, PDGF also directly stimulates endothelial cell growth, thus, it is of interest whether under pathological conditions or after massive anti-VEGF therapy, PDGF becomes a major player to stimulate the proliferation of vascular endothelial cells or not.
Anti-angiogenic pathways independent of VEGF signaling
Angiostatin and endostatin were reported to be natural anti-angiogenic proteins in the body. However, their receptors and the molecular basis of their actions are still not clear, thus, their anti-angiogenic effects on tumors in mammals should be extensively studied.
TSP-1 (thrombospondin-1), BMP4 (bone morphogenetic protein 4), chondromodulin and others are reported to have anti-angiogenic activity in vitro and in vivo. Using a transgenic mouse model for VEGF-E under the control of the K14-promoter, we found that TSP-1 is secreted from epithelial basal cells and suppresses the pro-angiogenic effect of VEGF-E which was also secreted from the basal cell layer. TSP-1 has been studied in many laboratories, and it was proposed that CD36, a receptor for TSP-1 expressed in vascular endothelial cells, plays a major role in the anti-angiogenic pathway. However, we have found that the growth of HUVECs not expressing enough CD36 is suppressed by TSP-1 via a novel mechanism. In HUVECs, TSP-1 induced expression of p21 and unphosphorylated form of Rb, resulting in cell growth arrest and anti-angiogenesis (73) .
BMP4 is usually thought to promote morphogenesis in embryos including angiogenesis. Interestingly, we have shown that BMP4 is an important anti-angiogenic factor in the degeneration of the vascular network in the papillary membrane in newborn mice. Furthermore, the response to BMP4 differs with the type of endothelial cell. Venous and capillary endothelial cells are sensitive to BMP4, being apoptotic cell death in the presence of BMP4. On the other hand, arterial endothelial cells are resistant to BMP4-induced apoptosis, most likely due to the specific gene expression of "inhibitory Smads" such as Smad6 and Smad7 (74, 75) . The levels of inhibitory Smads (I-Smads) are very low in venous and capillary endothelial cells, suggesting that a difference in Notch signaling in arterial and venous endothelial cells results in a different expression of I-Smads. Some of these anti-angiogenic molecules acting independently of VEGF-signaling could be good candidates for drugs to treat patients with tumors resistant to anti-VEGF-VEGF R drugs and patients with chronic inflammation such as RA patients.
Conclusion
Under physiological and most pathological conditions, VEGF and VEGFRs are crucial for the formation and maintenance of blood vessels. Thus, VEGF-VEGFR inhibitors are now widely used for a variety of solid tumors all over the world. However, after extensive treatment, tumor tissues and tumor vessels might change and acquire resistance to these drugs. Therefore, VEGF-independent pathways as well as VEGF signaling itself should be extensively studied for better understanding of the regulation of angiogenesis, and to develop novel anti-angiogenic drugs.
